New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
19:03 EDTAGEN, IDIX, ARWR, HAIN, OCLR, IDRA, CHRW, MYGN, MMM, GNWOn The Fly: After Hours Movers
UP AFTER EARNINGS: Myriad Genetics (MYGN), up 14.5%... Genworth (GNW), up 5%... Oclaro (OCLR), up 5.6%. ALSO HIGHER: 3M (MMM), up 2% after the Dow member announced a $12B share repurchase plan... Idenix Pharmaceuticals (IDIX), up 7.3% after investment firm Baupost Group raised its stake in the company to more than 35% from roughly 27% and disclosed it was granted observer rights for meetings of Idenix's board and committees. DOWN AFTER EARNINGS: C.H. Robinson (CHRW), down 6.4%... Hain Celestial (HAIN), down 7.9%. ALSO LOWER: Agenus (AGEN), down 6.2% after announcing a public offering of common stock... Idera Pharmaceuticals (IDRA), down 3.8% after filing to sell common stock and warrants... Arrowhead Research (ARWR), down 3% after reporting a larger-than-expected quarterly loss and filing a $200M mixed securities shelf.
News For MMM;MYGN;GNW;OCLR;IDIX;CHRW;HAIN;AGEN;IDRA;ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 26, 2015
07:08 EDTAGENAgenus reports Q4 EPS (41c), consensus (16c)
Reports Q4 revenue $1.62M, consensus $620K. Target Milestones for 2015 include: Publication of the Phase 2 data for Prophage in newly diagnosed GBM in a peer reviewed journal. Explore options for the advancement of Prophage for newly diagnosed GBM to a Phase 3 trial. Full Phase 3 data for partner GlaxoSmithKlineís HZ/su shingles vaccine are expected to be presented at a scientific conference and submitted for publication in a peer-reviewed journal. The vaccine contains Agenusí proprietary QS-21 Stimulon adjuvant. EMA regulatory decision on GlaxoSmithKlineís malaria vaccine candidate RTS,S, which contains Agenusís QS-21 Stimulon adjuvant. File Investigational New Drug applications for two checkpoint modulator antibody programs as part of our global oncology alliance with Incyte.
February 24, 2015
16:28 EDTMYGNMyriad Genetics board approves $200M increase in share buyback program
Subscribe for More Information
07:31 EDTIDRARBC Capital to hold a conference
Subscribe for More Information
February 23, 2015
16:24 EDTOCLRSoros Fund reports 9.95% passive stake in Oclaro
Subscribe for More Information
14:44 EDTMMM3M confirms agreement to acquire Polyporeís Separations Media business for $1B
3M (MMM) announced that it has entered into a definitive agreement with Polypore International (PPO) to acquire the assets and liabilities associated with Polyporeís Separations Media business for a total purchase price of $1B. Polyporeís Separations Media business is a leading provider of microporous membranes and modules for filtration in the life sciences, industrial and specialty segments with trailing 12-month sales of $210M as of Sept. 27, 2014. Separately, Asahi Kasei has announced that it has entered into a definitive merger agreement to acquire Polyporeís Energy Storage business. Both transactions are subject to regulatory approvals and customary closing conditions. In addition, both transactions are conditioned on 3Mís transaction with Polypore closing immediately prior to the closing of Asahi Kaseiís transaction with Polypore.
12:21 EDTMMMOn The Fly: Midday Wrap
Subscribe for More Information
07:33 EDTARWRArrowhead initiates dosing in phase 1 trial of ARC-AAT
Subscribe for More Information
05:34 EDTMMM3M expects acquisition of Polypore business to be dilutive to earnings
Subscribe for More Information
05:31 EDTMMM3M acquires Polypore's Separatoins Media Segment for $1B
As an integrated step in Polypore's (PPO) sale to Asahi Kasei for $60.50, immediately prior the transaction, 3M (MMM) will acquire the assets of Polypore's Separations Media segment for approximately $1band Asahi Kasei will receive the cash proceeds from the asset sale. The definitive agreements require that the sale of the Polypore and the integrated sale of the Separations Media segment close after closing conditions for both transactions have been satisfied and that the closings of the transactions are conditioned upon one another.
05:29 EDTMMMPolypore agrees to sell company for $60.50 per share
Subscribe for More Information
February 20, 2015
15:31 EDTHAINHain Celestial acquires health and beauty products maker Belvedere
Hain Celestial announced the acquisition of Belvedere International, a health and beauty care products maker. "We are excited by the acquisition of the Live Clean brand, which expands our presence in the personal care category and complements our Avalon Organics, Alba Botanica and JASON brands that we sell into Canada. This acquisition increases the scale of our Canadian operations to over $150M in net sales and provides us with opportunities for sales expansion and cost efficiencies as we leverage our existing infrastructure in Canada and our manufacturing and research and development expertise in personal care," said Hain CEO Irwin Simon. The Live Clean brand is the leading natural hair care and baby care brand in Canada. In calendar year 2014 Belvedere had approximately $25M in net sales and is expected to be accretive to Hain Celestial's earnings in fiscal year 2016.
February 19, 2015
10:01 EDTMMM3M acquires health care products manufacturer Ivera Medical
3M announced that it has entered into a definitive agreement to acquire Ivera Medical, a manufacturer of health care products that disinfect and protect devices used for access into a patientís bloodstream. Terms of the transaction were not disclosed. Ivera employs approximately 60 people and has annual sales of approximately $30M. The transaction is expected to close in the first half of 2015. On a GAAP reported basis, 3M estimates the acquisition to be neutral to earnings in the first 12 months following completion of the transaction.
February 18, 2015
10:32 EDTGNWOptions with decreasing implied volatility
Subscribe for More Information
10:05 EDTCHRWOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:07 EDTMMMBarclays to hold a conference
Industrial Select Conference is being held in Miami on February 18-19.
06:38 EDTCHRWC.H. Robinson initiated with a Neutral at UBS
Subscribe for More Information
February 17, 2015
10:53 EDTMYGNScopia Capital reports 5.87% passive stake in Myriad Genetics
10:51 EDTGNW, ARWROptions with decreasing implied volatility
Subscribe for More Information
09:42 EDTIDRABaker Brothers Advisors buy 5.33M shares of Idera Pharmaceuticals
A filing by Idera Pharmaceuticals director Julian Baker showed that his Baker Bros. Advisors purchased about 5.33M shares of the company's stock in transactions on February 13 at an average price of $3.75 per shares. Idera Pharmaceutical shares are up 6.5% to $4.37 in early trading.
07:15 EDTHAINConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use